Pavion Blue Capital’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.66M Hold
1,805
0.72% 37
2025
Q4
$1.94M Buy
1,805
+5
+0.3% +$4.78K 0.81% 33
2025
Q3
$1.37M Hold
1,800
0.59% 38
2025
Q2
$1.4M Hold
1,800
0.62% 38
2025
Q1
$1.49M Hold
1,800
0.71% 38
2024
Q4
$1.39M Hold
1,800
0.65% 40
2024
Q3
$1.59M Sell
1,800
-1,143
-39% -$1.03M 0.74% 38
2024
Q2
$2.66M Hold
2,943
1.31% 25
2024
Q1
$2.29M Hold
2,943
1.13% 25
2023
Q4
$1.72M Hold
2,943
0.95% 33
2023
Q3
$1.58M Hold
2,943
0.96% 33
2023
Q2
$1.38M Buy
2,943
+100
+4% +$41.9K 0.8% 35
2023
Q1
$976K Hold
2,843
0.6% 44
2022
Q4
$1.04M Hold
2,843
0.66% 42
2022
Q3
$919K Hold
2,843
0.66% 42
2022
Q2
$922K Hold
2,843
0.62% 42
2022
Q1
$814K Buy
2,843
+700
+33% +$180K 0.48% 49
2021
Q4
$592K Hold
2,143
0.34% 55
2021
Q3
$495K Hold
2,143
0.31% 56
2021
Q2
$492K Buy
2,143
+443
+26% +$89K 0.3% 57
2021
Q1
$318K Hold
1,700
0.21% 64
2020
Q4
$287K Hold
1,700
0.2% 67
2020
Q3
$252K Hold
1,700
0.19% 70
2020
Q2
$279K Hold
1,700
0.24% 63
2020
Q1
$236K Hold
1,700
0.24% 63
2019
Q4
$223K Buy
+1,700
New +$197K 0.22% 56

Other funds holding LLY

Pavion Blue Capital's LLY Position: Q1 2026 in Review

Pavion Blue Capital held its Eli Lilly (LLY) position steady in Q1 2026 at 1,805 shares worth $1.66M. The position accounts for 0.72% of the portfolio, ranked #37.

Pavion Blue Capital first reported a position in LLY in Q4 2019 and has held it in 26 quarters since. The position peaked at $2.66M in Q2 2024. 4,355 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Pavion Blue Capital held 1,805 shares of Eli Lilly worth $1.66M as of Q1 2026.
  • Pavion Blue Capital left its Eli Lilly share count unchanged in Q1 2026.
  • Eli Lilly made up 0.72% of Pavion Blue Capital's portfolio in Q1 2026, its #37 holding.
  • Pavion Blue Capital first reported a position in Eli Lilly in Q4 2019 and has held it in 26 quarters since.
  • Pavion Blue Capital's Eli Lilly position peaked at $2.66M in Q2 2024.
  • 4,355 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Pavion Blue Capital's 13F filing for Q1 2026, filed 6 May 2026.